Ad
related to: the latest medication for cml- Safety Information
Read the Important Safety Info
about this treatment option for CML
- Treatment Info Available
See how this treatment option
works. Talk to your doctor today.
- Safety Information
Search results
Results from the WOW.Com Content Network
Asciminib, sold under the brand name Scemblix, is a medication used to treat Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). [5] [7] [8] Asciminib is a protein kinase inhibitor. [5] The most common adverse reactions include upper respiratory tract infections, musculoskeletal pain, fatigue, nausea, rash, and diarrhea. [7]
Dasatinib, sold under the brand name Sprycel among others, is a targeted therapy medication used to treat certain cases of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). [3] Specifically it is used to treat cases that are Philadelphia chromosome-positive (Ph+). [3] It is taken by mouth. [3]
The treatment options for imatinib resistant or intolerant CML patients may include strategies such as increasing the dose of imatinib or the use of second-generation drugs. Escalation of imatinib-doses has shown to overcome some cases of primary resistance to imatinib, such as Bcr-Abl duplication, but the response is usually short acting. [ 2 ]
Ponatinib, sold under the brand name Iclusig, is a medication used for the treatment of chronic myeloid leukemia and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia. [4] It was developed by Ariad Pharmaceuticals. It is a multi-targeted tyrosine-kinase inhibitor. [5]
Due in part to the development of imatinib and related drugs, the five-year survival rate for people with chronic myeloid leukemia increased from 31% in 1993, to 59% in 2009, [13] to 70% in 2016. [14] By 2023, the five year survival rate for people with chronic myeloid leukemia had risen to 90%. [15]
Discover the latest breaking news in the U.S. and around the world — politics, weather, entertainment, lifestyle, finance, sports and much more.
Nilotinib, sold under the brand name Tasigna among others, is a anti-cancer medication used to treat chronic myelogenous leukemia (CML) which has the Philadelphia chromosome. [3] [7] It may be used both in initial cases of chronic phase CML as well as in accelerated and chronic phase CML that has not responded to imatinib. [3] [7] [8] It is ...
Treatment of adults with newly diagnosed Philadelphia chromosomepositive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) [2] Blinatumomab Treatment of CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy in people aged one month of age ...
Ad
related to: the latest medication for cml